Form 4: GNI Group Reports Gyre Therapeutics Equity Acquisition

GNI Group Ltd. and GNI USA, Inc. reported the acquisition of Series B Preferred Stock in Gyre Therapeutics, Inc. following the merger with Cullgen Inc.

Summary

• GNI Group Ltd. and its subsidiary GNI USA, Inc. acquired a combined 2,601,826 shares of Series B Preferred Stock in Gyre Therapeutics, Inc. (GYRE).
• The acquisition occurred on May 4, 2026, as part of the merger between a subsidiary of Gyre Therapeutics and Cullgen Inc.
• Each share of Series B Preferred Stock is convertible into five shares of common stock, subject to stockholder approval and beneficial ownership limitations.
• The transaction results in an indirect beneficial ownership of 13,009,130 common shares upon conversion.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral, procedural disclosure confirming the completion of a previously announced strategic merger.

Positives

• The transaction reflects the successful completion of the merger between Gyre Therapeutics and Cullgen Inc.
• GNI Group maintains a significant 10% ownership stake, signaling long-term strategic alignment with the issuer.

Negatives

• The conversion of Series B Preferred Stock into common stock is subject to future stockholder approval, creating a dependency on corporate governance outcomes.

Risks

• Beneficial Ownership Limitations may restrict the ability of the reporting person to convert preferred stock into common stock at their discretion.
• The value of the investment is tied to the successful integration and performance of the newly acquired Cullgen Inc. subsidiary.

Future Outlook

The conversion of the Series B Preferred Stock into common stock is contingent upon receiving stockholder approval, with no expiration date currently set for the preferred securities.

Management Comments

• The reporting persons note that GNI USA may be deemed the indirect beneficial owner of securities held by GNI Japan, and vice versa, for Section 16 purposes.

Industry Context

StockSavvy.ai notes that this filing highlights the ongoing consolidation in the biotechnology sector, where parent companies are utilizing preferred equity structures to facilitate strategic mergers and maintain significant influence over post-merger entities.

Comparison to Industry Standards

• The use of Series B Preferred Stock as merger consideration is a standard mechanism in biotech M&A to manage dilution and provide tax-efficient equity transfers.
• The 5:1 conversion ratio is consistent with typical venture-backed biotech capital structures.

Corporate Governance

Related Party Transactions

• GNI Group Ltd. and GNI USA, Inc. are related parties, with GNI USA being a wholly-owned subsidiary of GNI Group.

Stakeholder Impact

• Existing shareholders may face potential dilution if the Series B Preferred Stock is converted into common stock following stockholder approval.

Next Steps

• Obtain stockholder approval to enable the conversion of Series B Preferred Stock into common stock.

Key Dates

Keywords

Gyre Therapeutics, GNI Group, Cullgen, Merger, Series B Preferred Stock, SEC Form 4, Beneficial Ownership